Introduction
Techniques for sequencing RNA and DNA pioneered by Fred Sanger and others in the 1960s [1] and 1970s [2] began to reveal the biochemical recipes for storing biological information in organisms and laid the foun da tion for modern genomics. Yet, decades before the fi rst nucleic acid was sequenced, various chemical modi fi cations of DNA had already been described, such as 5-methylcytosine [3] and 5-hydroxy-methylcytosine [4] , now dubbed the 5th [5] and 6th [6] base of genetics; in total, several dozen DNA modifi cations have been reported [7] . Th ese modifi cations, along with histone modi fi cations, are now recognized as important regula tory mechanisms for controlling gene expression and function [8] .
Fortunately, it is now relatively easy to characterize these modifi ed DNA bases, which form part of the 'epi'-genome (epi, on top), for any organism with a fi nished genome, given the widespread availability of highthrough put techniques, especially those based on nextgeneration sequencing (NGS). Various NGS approaches are being used in the National Institutes of Health (NIH)'s Epigenomics Roadmap [9] and in the BLUEPRINT Project [10] . Similarly, cell-specifi c, post-translational modi fi cations of proteins, sometimes referred to collectively as the 'epiproteome' [11] , are essential mechanisms necessary for the regulation of protein activity, folding, stability and binding partners. Elucidating the roles of protein and DNA modifi cations has had a major impact on our understanding of cellular signaling, gene regulation and cancer biology [12] .
However, our understanding of an additional regulatory layer of biology that rests between DNA and proteins is still in its infancy; namely, the multitude of RNA modifi cations that together constitute the 'Epitranscriptome' . Th ere are currently 107 known RNA base modifi cations, with the majority of these having been reported in tRNAs or rRNAs [13] . Outside the 5' cap, the role of modifi cations in mRNA is unclear [14, 15] . One RNA modifi cation, N6-methyladenosine, or methyl-6-adenosine (m 6 A), has been observed in a wide variety of organisms, including viruses [16] , yeast [17] , plants [18] , humans [19, 20] and mice [19, 20] , and exhibits dynamic changes in response to a variety of stimuli in yeast [21] . Older studies using purifi ed polyadenylated RNA from mammalian cells showed that m 6 A was the most abundant post-transcriptional modifi cation in polyadenylated RNA [14] , which contemporary doctrine considered to be synonymous with mRNA. However, it is now known that polyadenylation occurs not only on mRNAs, but also in other RNAs, such as rRNAs and long intergenic noncoding RNAs (lincRNAs). Th us, it was historically unclear exactly how m 6 A existed in mRNAs and, if so, whether it was restricted to a select few transcripts or prevalent throughout the transcriptome.
Previous methods for investigating the prevalence of m 6 A were laborious and involved incubating cells with 14 C-radiolabeled methionine (the precursor for the endogenous methyl donor, S-adenosylmethionine), following which the incorporation of methyl groups into RNAs could be quantifi ed. Th ese early studies detected methylated bases in ribosomal RNA (rRNA) [22] , small RNA fractions [23] [24] [25] [26] [27] and in mRNAs [28] . However, these methods were limited by their inability to identify the specifi c mRNAs that contained m mammalian mRNA (bovine prolactin [29] ), and the specific sites of m 6 A incorporation had been established for only two RNAs: prolactin [29] and Rous sarcoma virus RNA [30, 31] . The methods used to map these m 6 A sites were technically challenging and, more importantly, required a pre-ordained focus on a particular transcript, rather than a global approach that could detect sites of adenosine methylation in all mRNAs. Moreover, adenosine methylation is invisible, insofar as both methylated and non-methylated adenosines readily base pair with T or U, and both are reverse transcribed to T, further hindering the study of m 6 A and its role in biology. However, a renewed interest in m 6 A has recently emerged, partially due to the finding that the fat massand obesity-associated (FTO) gene encodes a brain-and hypothalamus-enriched m 6 A demethylase that is responsible for converting m 6 A to adenosine [32] . Defects in this enzyme result in significant alterations in energy use and metabolism, and mutations in FTO have recently been linked to a higher risk for Alzheimer's disease and decreased brain mass [33, 34] . These studies suggest that m 6 A may have a physiological role in cellular signaling and neurodegeneration. Recent advances in NGS technology, in addition to the availability of antibodies that recognize m 6 A, have enabled the development of global approaches for studying m 6 A. Recently, two groups have independently developed high-throughput methods for rapid characterization of m 6 A sites across the transcriptome. Methods such as methyl-RNA-immunoprecipitation-sequencing (MeRIP-seq) [19] or m 6 A-seq [20] , which combine immunoprecipitation (IP) of methylated RNAs using an m 6 A-specific antibody, with NGS, have finally opened the door to global methods for studying the epitranscriptome and its dynamics.
Mapping the epitranscriptome
Although MeRIP-seq and m 6 A-seq were developed independently [19, 20] , both are very similar in the initial RNA preparation and IP steps. The larger differences between the two protocols lie in their downstream compu tational methods rather than in sample preparation, which in both cases followed methods similar to existing chromatin IP-seq (ChIP-seq), insofar as they performed IP with an m 6 A-specific antibody. Table 1 shows the similarities and differences between the MeRIP-seq and m 6 A-seq protocols. Both datasets produced qualitatively similar results, with m 6 A peaks in introns, 5' UTRs, exons, splice junctions, ncRNAs and intergenic regions, indicating that m 6 A is a widespread and wide-ranging RNA modification. The MeRIP-seq study also identified peaks in lincRNAs. The genomic features for which m 6 A was particularly enriched are listed in Table 1 ; the main discrepancy between the two studies in this regard concerned the enrichment of m 6 A at transcription start sites (TSSs), which was observed by m 6 A-seq, primarily in a single cell line ( Figure 1a ). An explanation for this discrepancy may be the different window used to define the TSS. A comparison between mouse and human data in both studies showed a high conservation of specific m 6 A sites across the two species. Finally, digesting samples with various RNases prior to MeRIP-seq demonstrated that m 6 A sites were mostly present at internal sites within mRNAs and were absent from polyA tails.
In addition to sequencing, the MeRIP-seq study also used immunoblotting to investigate m 6 A, demonstrating that m 6 A is present in mouse heart, lung, brain, liver and kidney tissues, with a particular enrichment in brain, liver and kidney. High levels of m 6 A were found in HepG2 and MCF7 cells, in contrast to lower levels detected in other human cancer cell lines (PC3 and PC9). The dynamic nature of m 6 A was confirmed by comparing embryonic with adult tissue, which showed that m 6 A levels increase over the course of development. The m 6 Aseq study also found m 6 A to be a dynamic modification, finding that its distribution changed in response to a variety of external stimuli (ultraviolet, interferon gamma, hepatocyte growth factor and heat shock), although as many as 70 to 95% of the peaks were static.
Experiments leveraging the depletion of the METTL3 subunit responsible for methylating adenosines were used in the m 6 A-seq study to explore the modification's function. A statistically significant increase in the abundance of alternatively spliced transcripts was observed as a result of this depletion, with the alternatively spliced exons and introns showing an enrichment for m 6 A peaks. However, a permutation analysis of splice junctionlocalized m 6 A sites in the MeRIP-seq study data did not find a statistically significant enrichment of m 6 A peaks in the proximity of splice junctions [19] . Moreover, an analysis of the total mapped bases from the MeRIP-seq samples versus the control, non-IP RNA samples showed that fewer bases mapped to splice junctions in the IP samples (Additional file 1). Elucidating whether m 6 A functions in splicing and, if so, whether this is direct or indirect through the regulation of splicing factorencoding transcripts, will require further investigation. In light of the MeRIP-seq data, we suggest that m 6 A is not likely to cause an overall increase in the global amount of transcript splicing, but it may modify splicing for certain classes of genes, and particularly for genes with alternative, internal exons [20] .
Challenges of epitranscriptomic site detection
There are many factors to consider when computing the m 6 A enrichment for a site. For example, the definition of gene regions, the gene isoform used, the presence of secondary structure, the alignment method and the read depth can all impact the degree of enrichment discovered. Given that epitranscriptomics is a nascent field, computational analysis methods are only now emerging. Here, we explore the impact of these factors on detecting and quantifying m 6 A. A comparison of the raw peaks found in the MeRIP-seq and m 6 A -seq studies showed surprisingly little overlap, even with a single base threshold (Table 2) . However, the different cell types used, as well as slightly different RNA handling methods, likely account for some of these peak differences [19, 20] . Another technical contributor to the low overlap may be erroneous methylation calls, given that the false discovery rate (FDR) for both methods was 5 to 7%. The overlap notably improved when bases in transcripts with low expression levels were excluded (Table 3) . These complications notwithstanding, the total number of m 6 A sites identified encompassed the majority of human genes and almost one-third of mouse genes ( Table 2) .
We re-analyzed the datasets from both studies in order to determine the effect of the peak-calling method on the apparent m 6 A distribution in the transcriptome and found two discrepancies. By comparing peak-calling methods, we observed that the presence of the 5' UTR peak in the m 6 A-seq dataset was attenuated when that study's peak-caller was replaced by MeRIPPeR [35] from the MeRIP-seq study. This reduction indicates that each of the two peak-calling algorithms may have different sensitivities and specificities.
We also note that the 5' UTR m 6 A signal in the original peak sets used a definition of a TSS that was 150 bp, and that the signal was primarily derived from larger genes, as measured by exon number ( Figure 2 ); a potential m 6 A enrichment within these genes can be seen at the end of the first intron and at the beginning of the following exon ( Figure 2 ). Since the distribution of the m 6 A sites is nonuniform (in the sense that enrichment is dependent on the number of exons in a gene and that on the context of an exon within a gene), a useful method to examine m 6 A localization, or any epitranscriptomic change, may be to separate the genes into their sub-geographies ( Figure 3 ).
m 6 A mapping is heavily impacted by the read depth and by the choice of peak detection and alignment methods
To further investigate the analytic dependency of m 6 A peak detection, we examined the m 6 A site detection as a function of alignment method, antibody and read depth. Part of the challenge of MeRIP-seq analysis is a reliance on other IP-seq analysis methods, developed for chromatin IP-seq (ChIP-seq). ChIP-seq experiments are designed to characterize DNA-histone and DNAtranscription factor interactions. Existing ChIP-seq peakfinders take advantage of inherent properties of the data to assist in finding peaks, many of which do not apply in the case of finding m 6 A sites in RNA. For example, each fragmented RNA molecule pulled-down by an m 6 A antibody has the potential to harbor far more methylation A sites are more challenging to resolve. ChIP-seq peak fi nders use diff erent methods and heuristics to fi nd peaks, attempting to balance fi nding weak peaks with maintaining a low FDR and resulting in a diverse group of peak sets [36, 37] . Th e same is true for m 6 A peaks, as the MeRIP-seq study used Fisher's exact test and the m 6 Aseq study derived a window score based on peak enrichment.
Each of the multiple methods for aligning reads to a transcriptome has its own set of advantages and challenges. A genome-based aligner, such as BWA [38] , can be used when a genome sequence is available, but introduces added complexity when reads map to multiple transcript variants, and suff ers from being unable to align reads to genomic regions that are absent from a predefi ned reference. Alternatively, a gap-based aligner, such as TopHat [39] or GSNAP [40] , can be used, with the advantage that these algorithms are designed for transcriptomes and so can map reads across both known and novel splice junctions. However, these methods tend to be slower and can introduce many false splice sites, leading to poorly aligned reads. Th e ability of an aligner to handle errors typical of RNA-seq, which diff er to those seen in DNA sequencing, is another factor to consider. A common source of error in RNA-seq is the random hexamer priming used in cDNA synthesis, which introduces a bias in the nucleotide distribution at the beginning of reads [41] . One possible solution to this particular error is to trim the reads, an approach that was employed in the m 6 A-seq study. To examine the eff ect of aligner on the detection of m 6 A peaks, we analyzed processed HEK293T MeRIP-seq data using three aligners (BWA [38] , TopHat 2 [39] and GSNAP [40] ), and then called peaks with MeRIPPeR [35] . We observed a slight increase in the number of 5' UTR peaks when using the transcriptome aligners GSNAP and TopHat 2 relative to the number called when using BWA (Additional fi le 2). More importantly, there was a significant increase in the number of individual peaks: MeRIPPeR found 19,617 peaks using BWA, 45,738 with GSNAP and 135,706 using TopHat 2, all at the same FDR (0.05). Th ese results indicate that the alignment method selected has a signifi cant impact on the number of peaks identifi ed in a MeRIP-seq dataset.
To eff ectively gauge the infl uence of read depth on m 6 A site detection, we used a sub-sampling titration analysis of the aligned reads. We found that peak detection is heavily dependent on read depth (Additional fi le 3a), with some aligners showing a nearly linear increase in peaks as a function of depth. Th e number of genes in which these peaks were found also increased with read depth, albeit less dramatically (Additional fi le 3b), with The distribution of peaks across the transcriptome using the BWA-based MeRIPPeR pipeline [35] on the data from both groups. Data from [19] and [20] . CDS, coding sequence. The total number of genes that overlap with m 6 A sites in at least one of the two datasets ('total genes with m 6 A') is shown for both human and mouse. The overlap between the two datasets ('common genes') is small. The number of genes reported in one dataset only for each of the datasets is also shown. A sites in at least one of the two datasets ('expressed genes with m 6 A') is shown for both human and mouse. The overlap between the two datasets ('common genes'), as a proportion of the total number of expressed genes with m 6 A, is much higher than the proportion shown in Table 2 .
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the number of genes continually increasing as a function of depth. While a specifi c point in a transcript might be correctly called as an m 6 A site, it is not known if the site is methylated in all copies of that transcript [19] . Th e percentage of transcripts at which a site is methylated may be quantifi ed as the stoichiometry of m 6 A. It is likely that the new peaks detected with increasing read depth are low in m 6 A stoichiometry and hence more challenging to detect at lower read depths. From these data, we extrapolate that, given enough tissues, cell types and conditions, it is possible that almost all genes may be marked, at some point, by m A peaks by both studies, each of which used a diff erent motif-fi nding algorithm, and both analyses suggest that the A in the canonical motif is the methylated siteagreeing with prior work in m 6 A sequence specifi city [42, 43] . Both groups found the motif to be highly enriched in peak regions compared with negative control regions. If the A in the motif is indeed the m The peak distribution depicted is the average across the entire transcriptome. Peaks are mapped to transcripts and assigned to the following transcriptomic features: 1 kB upstream from the TSS and downstream from the transcription end site, 5' and 3' UTRs, coding segments (CDS), and exon and intron segments. In the bottom row, peaks mapping to transcripts with four or more exons are shown, with the fi rst, penultimate and last exons separated into individual boxes, as are their neighboring introns. The remaining exons and introns are shown in the middle boxes as a contiguous segment. Genes with only two or three exons are shown in the middle row and single exon genes are shown in the top row. Data from [19] and [20] . A sites across gene bodies is very similar to the peak distribution (Figure 1a) .
However, we did not observe an enrichment of m 6 A sites in the 5' UTR, and the coding sequence profi le is fairly fl at until the peak reaches the proximity of the stop codon. Th is could indicate that the identifi ed [AG]ACU motif is specifi c to those peaks near the stop codon, or that the peak enrichment near the 5' UTR does not refl ect a true increase in the number of actual m 6 A sites. To test whether the motif was specifi c to stop codonproximal regions, we performed a FIRE [44] motif fi nder analysis of the 5' UTR peaks that were present in the MeRIP-seq mouse liver dataset, since this dataset was not enriched for this motif in this genomic region. Nonetheless, FIRE found a [CG]ACU motif, though not the strongest motif, indicating that it is not specifi c to the stop codon peaks, and thus likely a global motif for m 6 A, but perhaps weakly represented in the 5' UTR.
Single-molecule approaches to RNA modifi cations
Single-molecule sequencing has the potential to provide base-level resolution of m 6 A sites, without the need for motif-based inference. Th e most commonly found platform for this method of sequencing currently on the market is the single-molecule, real-time (SMRT) technology (Pacifi c Biosciences). SMRT sequencing uses thousands of zero-mode waveguides (ZMWs) to capture an enzyme in real time, traditionally a DNA polymerase, as it incorporates fl uorescent nucleotides into a polymer [45] . Th is method of molecular monitoring has the advantage of detecting both genetic and epigenetic information simultaneously, since the patterns of base incorporation by the polymerase are contingent upon the steric and sequence contexts of the bases present in the template [46] . Specifi cally, if a modifi ed base is present on the template, the biophysical dynamics of DNA polymerase movement and base incorporation are aff ected, creating a unique kinetic signature before, during and after base incorporation, and thus enabling identifi cation of specifi c DNA modifi cations [47] .
Here, we report a novel application of this technology, which can be used to detect modifi ed bases within RNA, including m 6 A sites. To characterize m 6 A sites in RNA at single-nucleotide resolution, we used a reverse transcriptase as the enzyme within a ZMW, instead of a DNA polymerase, and this substitution allowed the direct observation of cDNA synthesis in real time. While base incorporations during reverse transcription typically occur at standard speeds, the incorporation of synthetically designed m 6 A sites showed that there is a signifi cant increase in the inter-pulse duration (IPD) when a methylated adenosine is present in the RNA template, relative to the IPD for a standard adenosine (Figure 4 ). To our knowledge, this represents the fi rst demonstration of a reverse transcriptase-based kinetic signature that can directly detect modifi ed RNA. However, current singlemolecule technology is not without its own challenges. First and foremost, reverse transcriptases stutter when incorporating bases, complicating the accurate reading of homonucleotide stretches and the base resolution of m 6 A therein. Second, the current throughput is too low for transcriptome-wide approaches. Notwithstanding these caveats, the SMRT technology has the clear potential to detect an underlying epitranscriptomic change in a native RNA template.
Similarly, Oxford Nanopore Technologies (ONT) and other companies are developing nanopore-based sequencing technologies, which use nanopore-forming proteins to sequence DNA by attaching an application-specifi c integrated circuit to the membrane upon which the nanopore rests. In principle, observations of any modifi ed DNA or RNA base could be made during transit of the molecule through the nanopore, and some observations have already been made with nanopores that allow detection of 5hmC [48] . While all of these technologies are still under development, we note that all directobservation methods, in principle, have the potential to detect m 6 A and other epitranscriptomic modifi cations.
Beyond m 6
A: mapping the full epitranscriptome As mentioned previously, m 6 A is only one of many known epitranscriptomic modifi cations, the majority of which are located in tRNA and rRNA transcripts. We used data from the RNA Modifi cation Database to A sites within peaks, and the distribution of these potential sites across gene bodies plotted. Data from [19] and [20] . As. The average IPD in each case is the revers e of the exponential decay rate. The error bars indicate the range around each average IPD that includes 83% of the observed IPDs (that is, ±½ of standard deviation of the exponential fi t). We used an AnsariBradley test in Matlab to confi rm that the distribution functions were diff erent (P = 0.0043). 
summarize the catalog of known RNA modifications by species, RNA type and base ( Figure 5 ) [13] .
Interestingly, the enzyme commonly known as DNA methyltransferase-2 (DNMT2) [Swiss-Prot: O14717] was shown to methylate cytosine 38 of tRNA Asp [49] , and with such high specificity that it was renamed tRNA aspartic acid methyltransferase 1 (TRDMT1). More recently, two more tRNAs were found to be methylated by TRDMT1, and it was also observed that the methylation protects the tRNA from stress-induced cleavage and improves its stability [50, 51] . Several tRNA nucleoside modifications have been shown to control frame shifting and codon binding during translation. These types of modifications often occur in the crucial 7 bp anticodon stem and loop (ASL) region that binds to mRNA codons in ribosomes, and are hypothesized to affect the stability and codon binding affinity during translation by controlling the overall shape of the loop and its dynamics [52] [53] [54] . Taken together, a pattern emerges in which RNA modifications in multiple RNA species act as a critical regulatory layer of RNA biology.
Many RNA modifications would benefit from a more global and cross-species characterization than is present in the existing literature. For example, studies in Escherichia coli and yeast have shown that nucleotide modifications in rRNA lie in functionally significant regions, with a possible role in the regulation of translation [55] . Another example is methylation in plant rRNAs, where the modification is thought to help maintain rRNA stability, possibly in order to sustain ribosomal function during dramatic changes in temperature [56] . Interestingly, rRNA modifications in trypanosomes were shown to be mediated by small nucleolar RNAs (snoRNAs) [57] , and changes in pseudouridylation of rRNA in mice, induced by mutations in DKC1 [SwissProt: Q9ESX5], led to the onset of dyskeratosis congenital, resulting in an increase in tumor susceptibility [58] .
Taken together, these studies demonstrate the possible significance and functional importance of (r/t/m/mi/sno/ linc)RNA modifications and begin to sketch out what might be called a transcriptomic regulome, where various species of coding and noncoding [59] RNAs, as well as their modified epitranscriptomic variants, compete with, coordinate and control each other during normal cellular processes, from the birth of a transcript until the production of its subsequent protein product or localization of its cellular target. 
Conclusions
Characterizations of m 6 A across the transcriptome show that m 6 A is present in the majority of mammalian genes, and is highly enriched at the beginning of the 3' UTR and near the stop codon. Yet, many peaks exist in intergenic regions or in introns, and there is some evidence that m 6 A functions in the regulation of splicing or other modifications that take place in the processing of RNA into a mature transcript. Since m 6 A distribution has already been shown to undergo developmental changes and differences in cancer cell lines, it is also possible that epitranscriptomic signatures may be used to stratify various states of disease, just as in epigenetics [60] . Despite these advances, the complete purpose and molecular function of m 6 A is still unknown. Nonetheless, some reasonable hypotheses can be proposed from the existing data. The enrichment of m 6 A sites near the stop codon suggests that the modification could play some role in regulating translation termination, potentially by altering translation efficiency or ribosome occupancy. In addition, m 6 A may mark transcripts for shuttling to RNA granules or for other mechanisms that will preserve the RNA for later use. Just as the number of known modifications of RNA has rapidly expanded (currently 107), the number of known RNAbinding proteins similarly keeps growing, and it is possible that some of these may be responsible for altering the function of m 6 A within RNAs, either directly or through the regulation of FTO or METTL3. Such interactions could occur at any point of transcription, post-transcriptional modification or translation, with different consequences at each stage in the life of an mRNA. Finally, it is also possible that some RNA binding proteins may be m 6 A site scanners that bind selectively to either methylated or unmethylated RNA, and as such would be regulated by the epitranscriptomic state of an RNA.
Two additional avenues warrant consideration when discussing possible regulatory functions of m 6 A. First, even though an inverse spatial relationship was observed between m 6 A peaks and microRNA (miRNA) binding sites in 3' UTRs [19] , it is notable that brain tissue is enriched for both highly expressed miRNAs and m 6 Acontaining genes, which suggests that miRNAs might influence the methylation of a targeted mRNA. In addition, recent work has shown an interplay of mRNA methylation and the reduction of Dicer activity, thus decreasing miRNA maturation rates [61] . Second, m 6 A has already been shown to inhibit RNA editing in certain cases [62] , implying that m 6 A may serve as the longsought balancing mechanism for the prevention of RNA editing [63] . If it is the case that m 6 A prevents RNA editing from occurring, then evidence for this should be apparent in a diminished overlap between m 6 A and the target RNA editing sites. So far, this appears to be true [19] , but the number of sites examined is too low to be definitive yet. If upheld with additional experiments, these feedback and regulatory loops may help explain the genesis and changes in RNA editing sites and miRNA levels, and provide additional mechanisms for controlling gene expression and RNA function.
In summary, the high-throughput and single-molecule methods described here represent the dawn of new research into a novel, RNA-based regulatory layer in cells, which adds yet another component of regulatory complexity to the central dogma of molecular biology (Additional file 5). The high conservation of specific m 6 A sites across mouse and humans, as well as the general increase in PhyloP conservation scores of the m 6 A sites themselves [19] , both indicate that m 6 A is under strong evolutionary selection pressure, and thus may represent a critical modification for many organisms. Even though previous evidence indicates that m 6 A is an RNA modification present in all species, it has so far only been examined on a transcriptome-wide basis in two species (human and mouse), and observed in mRNAs only in eukaryotes, leaving open a wide area of research for many eukaryotic and prokaryotic systems. Just as the protein translation code and epigenetic code have slowly accreted into a cogent framework for information transfer and regulation within the cell, and between generations, these data indicate that an important epitranscriptome code is emerging. Notably, this dynamic code already appears to greatly expand the function and regulatory potential of all information contained within the many species of RNA present in a cell.
Methods
Sequence data were realigned to the genome using BWA [38] , TopHat 2 [39] or GSNAP [40] . BWA was run using default parameters, and GSNAP and TopHat 2 were inputted with known RefSeq transcript definitions and run with novel splice junction finding turned on. The aligned files were converted to bam files using SamTools [64] , filtering out reads with Phred quality scores under 20. BEDTools [65] was used to compute genome properties, such as coverageBed to compute genome coverage and RPKM (using a Perl script) and intersectBed to determine peak overlaps. Subsampling was accomplished using Picard's DownSampleSam [66] .
Peak-finding was accomplished using MeRIPPeR [35] and transcriptome profile plots were generated using Jenotator: Java Genome Annotator [67] . A custom R script was used for plotting the transcriptome profile plot and Excel 2013 was used to plot the other bar charts. rmake was used to generate genome annotation plots [68] . Motif regions were extracted using ChIPseeqer's ChIPseeqerMotifMatch [69] and individual m 6 A sites were extrapolated with a Perl script.
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